Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 9c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.04 --0%
EPS Growth %: -60.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
LGCY, UXIN, SCHL, More
EPS Growth %: -60.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
LGCY, UXIN, SCHL, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of ($0.08), $0.09 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $53.2 million versus the consensus estimate of $51.23 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2025 revenue of $210-250 million, versus the consensus of $284.9 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amazon to Expand Robot-Making Capacity With New, $100-Million Indiana Hub - WSJ
- Charles River sets 2030 targets, lifts 2026 earnings outlook
- StoneX Lowers Q3 Estimates for J.B. Hunt Transport Services (JBHT) on Higher Costs
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
